INBX - Inhibrx Biosciences Inc.
130.665
-0.785 -0.601%
Share volume: 379,225
Last Updated: 04-28-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.20%
PREVIOUS CLOSE
CHG
CHG%
$131.45
-0.78
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-13-2024 | 11-14-2024 | 03-17-2025 | 05-14-2025 | 11-13-2025 | 03-19-2026 | |
| Assets | ||||||||
| Total Assets | 288.577 M | 258.418 M | 222.562 M | 180.767 M | 242.639 M | 177.471 M | 146.478 M | |
| Current Assets | 274.538 M | 242.057 M | 207.446 M | 160.398 M | 223.386 M | 161.423 M | 132.832 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 19.017 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 19.017 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 3.038 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 252.483 M | 226.860 M | 196.332 M | 152.596 M | 216.520 M | 153.088 M | 124.220 M | |
| Total Non-current Assets | 14.039 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 6.966 M | 7.605 M | 6.879 M | 6.200 M | 5.546 M | 4.306 M | 3.733 M | |
| Other Assets | 7.073 M | 8.756 M | 8.237 M | 14.169 M | 13.707 M | 11.742 M | 9.913 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 288.577 M | 258.418 M | 222.562 M | 180.767 M | 242.639 M | 177.471 M | 146.478 M | |
| Total liabilities | 277.009 M | 39.052 M | 44.095 M | 47.183 M | 148.196 M | 140.641 M | 138.485 M | |
| Total current liabilities | 71.870 M | 39.052 M | 44.095 M | 40.730 M | 43.639 M | 35.983 M | 33.799 M | |
| Accounts Payable | 14.792 M | 13.021 M | 12.370 M | 9.245 M | 8.892 M | 6.773 M | 5.944 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 6.453 M | 5.904 M | 4.741 M | 4.127 M | |
| Current long term debt | 5.749 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 205.139 M | 0.000 | 0.000 | 0.000 | 98.653 M | 99.917 M | 100.559 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 6.453 M | 5.904 M | 4.741 M | 4.127 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 11.568 M | 219.366 M | 178.467 M | 133.584 M | 94.443 M | 36.830 M | 7.993 M | |
| Common stock | 54.554 M | 233.769 M | 236.734 M | 239.716 M | 243.886 M | 250.183 M | 254.180 M | |
| Retained earnings | -692.444 M | -14.403 M | -58.267 M | -106.132 M | -149.443 M | -213.353 M | -246.187 M |